GlassScriptPhysician profile
Beatriz Bautista
NPI 1437499738
$3,630.00
in general payments reported to CMS, 2019-2025
18 companies · $657 in 2025
The $657 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $429 · 2023: $873 · 2024: $784 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $570.00 | 2021 | |
| Lilly USA, LLC | $506.35 | 2023-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $415.24 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $408.80 | 2021-2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.27 | 2023-2024 | Jardiance |
| Amgen INC. | $167.85 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2024 | |
| Abbvie INC. | $132.92 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Intuity Medical INC | $124.49 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Nevro Corp. | $114.74 | 2023 | Senza |
| Lexicon Pharmaceuticals, INC. | $110.17 | 2024 | Inpefa |
| Dexcom, INC. | $108.32 | 2023 | Dexcom G7 Gss (161) |
| Ascensia Diabetes Care US INC. | $103.66 | 2025 | |
| Corcept Therapeutics | $100.03 | 2023 | Korlym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $98.25 | 2025 | Rezdiffra |
| Phadia US INC. | $83.02 | 2022 | |
| Insulet Corporation | $73.89 | 2024 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Bautista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.